6 Aptamers for Targeted Therapy
177
231. Baneshi M, Dadfarnia S, Shabani AMH, Sabbagh SK, Haghgoo S, Bardania H (2019) A
novel theranostic system of AS1411 aptamer-functionalized albumin nanoparticles loaded
on iron oxide and gold nanoparticles for doxorubicin delivery. Int J Pharm 564 (1873–3476
Electronic):145–152
232. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med
358(11):1160–1174
233. Dastjerdi K, Tabar GH, Dehghani H, Haghparast A (2011) Generation of an enriched pool
of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX. Biotechnol
Appl Biochem 58(4):226–230
234. Esposito CL, Passaro D, Longobardo I, Condorelli G, Marotta P, Affuso A, de Franciscis V,
Cerchia L (2011) A neutralizing RNA aptamer against EGFR causes selective apoptotic cell
death. PLoS ONE 6(9):e24071
235. Kim MY, Jeong S (2011) In vitro selection of RNA aptamer and specific targeting of ErbB2
in breast cancer cells. Nucleic Acid Ther 21(3):173–178
236. Sigismund S, Avanzato D, Lanzetti L (2018) Emerging functions of the EGFR in cancer. Mol
Oncol 12(1):3–20
237. Wang T, Philippovich S, Mao J, Veedu RN (2019) Efficient epidermal growth factor receptor
targeting oligonucleotide as a potential molecule for targeted cancer therapy. Int J Mol Sci
20(19):4700
238. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG,
Udove J, Ullrich A et al (1989) Studies of the HER-2/neu proto-oncogene in human breast
and ovarian cancer. Science 244(4905):707–712
239. Diaz-Rodriguez E, Perez-Pena J, Rios-Luci C, Arribas J, Ocana A, Pandiella A (2019) TRAIL
receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells.
Cancer Lett 453:34–44
240. Sawyers CL (2019) Herceptin: a first assault on oncogenes that launched a revolution. Cell
179(1):8–12
241. Ahmad A (2019) Current updates on trastuzumab resistance in HER2 overexpressing breast
cancers. Adv Exp Med Biol 1152 (0065–2598 Print):217–228
242. Moosavian SA, Jaafari MR, Taghdisi SM, Mosaffa F, Badiee A, Abnous K (2015) Development of RNA aptamers as molecular probes for HER2(+) breast cancer study using
cell-SELEX. Iran J Basic Med Sci 18(6):576–586
243. Gijs M, Penner G, Blackler GB, Impens NR, Baatout S, Luxen A, Aerts AM (2016) Improved
aptamers for the diagnosis and potential treatment of HER2-Positive cancer. Pharmaceut Basel
9(2):29
244. Shen Y, Li M, Liu T, Liu J, Xie Y, Zhang J, Xu S, Liu H (2019) A dual-functional
HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery
system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells. Int J
Nanomedicine 14 (1178–2013 Electronic):4029–4044
245. Mahlknecht G, Maron R, Mancini M, Schechter B, Sela M, Yarden Y (2013) Aptamer to
ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proc Natl
Acad Sci U S A 110(20):8170–8175
246. Kim HJ, Park JY, Lee TS, Song IH, Cho YL, Chae JR, Kang H, Lim JH, Lee JH, Kang WJ
(2019) PET imaging of HER2 expression with an 18F-fluoride labeled aptamer. PLoS ONE
14(1):e0211047
247. Naidu R, Yadav M, Nair S, Kutty MK (1998) Expression of c-erbB3 protein in primary breast
carcinomas. Br J Cancer 78(10):1385–1390
248. Chen CH, Chernis GA, Hoang VQ, Landgraf R (2003) Inhibition of heregulin signaling by
an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor
receptor-3. Proc Natl Acad Sci U S A 100(16):9226–9231
249. Nachreiner I, Hussain AF, Wullner U, Machuy N, Meyer TF, Fischer R, Gattenlohner S,
Meinhold-Heerlein I, Barth S, Tur MK (2019) Elimination of HER3-expressing breast cancer
cells using aptamer-siRNA chimeras. Exp Ther Med 18(4):2401–2412
177
231. Baneshi M, Dadfarnia S, Shabani AMH, Sabbagh SK, Haghgoo S, Bardania H (2019) A
novel theranostic system of AS1411 aptamer-functionalized albumin nanoparticles loaded
on iron oxide and gold nanoparticles for doxorubicin delivery. Int J Pharm 564 (1873–3476
Electronic):145–152
232. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med
358(11):1160–1174
233. Dastjerdi K, Tabar GH, Dehghani H, Haghparast A (2011) Generation of an enriched pool
of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX. Biotechnol
Appl Biochem 58(4):226–230
234. Esposito CL, Passaro D, Longobardo I, Condorelli G, Marotta P, Affuso A, de Franciscis V,
Cerchia L (2011) A neutralizing RNA aptamer against EGFR causes selective apoptotic cell
death. PLoS ONE 6(9):e24071
235. Kim MY, Jeong S (2011) In vitro selection of RNA aptamer and specific targeting of ErbB2
in breast cancer cells. Nucleic Acid Ther 21(3):173–178
236. Sigismund S, Avanzato D, Lanzetti L (2018) Emerging functions of the EGFR in cancer. Mol
Oncol 12(1):3–20
237. Wang T, Philippovich S, Mao J, Veedu RN (2019) Efficient epidermal growth factor receptor
targeting oligonucleotide as a potential molecule for targeted cancer therapy. Int J Mol Sci
20(19):4700
238. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG,
Udove J, Ullrich A et al (1989) Studies of the HER-2/neu proto-oncogene in human breast
and ovarian cancer. Science 244(4905):707–712
239. Diaz-Rodriguez E, Perez-Pena J, Rios-Luci C, Arribas J, Ocana A, Pandiella A (2019) TRAIL
receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells.
Cancer Lett 453:34–44
240. Sawyers CL (2019) Herceptin: a first assault on oncogenes that launched a revolution. Cell
179(1):8–12
241. Ahmad A (2019) Current updates on trastuzumab resistance in HER2 overexpressing breast
cancers. Adv Exp Med Biol 1152 (0065–2598 Print):217–228
242. Moosavian SA, Jaafari MR, Taghdisi SM, Mosaffa F, Badiee A, Abnous K (2015) Development of RNA aptamers as molecular probes for HER2(+) breast cancer study using
cell-SELEX. Iran J Basic Med Sci 18(6):576–586
243. Gijs M, Penner G, Blackler GB, Impens NR, Baatout S, Luxen A, Aerts AM (2016) Improved
aptamers for the diagnosis and potential treatment of HER2-Positive cancer. Pharmaceut Basel
9(2):29
244. Shen Y, Li M, Liu T, Liu J, Xie Y, Zhang J, Xu S, Liu H (2019) A dual-functional
HER2 aptamer-conjugated, pH-activated mesoporous silica nanocarrier-based drug delivery
system provides in vitro synergistic cytotoxicity in HER2-positive breast cancer cells. Int J
Nanomedicine 14 (1178–2013 Electronic):4029–4044
245. Mahlknecht G, Maron R, Mancini M, Schechter B, Sela M, Yarden Y (2013) Aptamer to
ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proc Natl
Acad Sci U S A 110(20):8170–8175
246. Kim HJ, Park JY, Lee TS, Song IH, Cho YL, Chae JR, Kang H, Lim JH, Lee JH, Kang WJ
(2019) PET imaging of HER2 expression with an 18F-fluoride labeled aptamer. PLoS ONE
14(1):e0211047
247. Naidu R, Yadav M, Nair S, Kutty MK (1998) Expression of c-erbB3 protein in primary breast
carcinomas. Br J Cancer 78(10):1385–1390
248. Chen CH, Chernis GA, Hoang VQ, Landgraf R (2003) Inhibition of heregulin signaling by
an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor
receptor-3. Proc Natl Acad Sci U S A 100(16):9226–9231
249. Nachreiner I, Hussain AF, Wullner U, Machuy N, Meyer TF, Fischer R, Gattenlohner S,
Meinhold-Heerlein I, Barth S, Tur MK (2019) Elimination of HER3-expressing breast cancer
cells using aptamer-siRNA chimeras. Exp Ther Med 18(4):2401–2412